本公司监事会及全体监事保证本公告内容不存在任何虚假记载、误导性陈述或者 重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 一、监事会会议召开情况 大参林医药集团股份有限公司（以下简称"公司"）第四届监事会第二十一 次会议通知于 2025 年 10 月 20 日发出，于 2025 年 10 月 29 日以通讯方式召开。 本次会议应到监事 3 人，实到监事 3 人，会议由监事会主席陈智慧先生召集并主 持。会议的出席人数、召集、召开及表决程序均符合《中华人民共和国公司法》 和《大参林医药集团股份有限公司章程》（以下简称"《公司章程》"）的有关规 定，会议决议合法、有效。 二、监事会会议审议情况 1、审议通过《关于公司 2025 年第三季度报告的议案》 证券代码：603233 证券简称：大参林 公告编号：2025-065 大参林医药集团股份有限公司 第四届监事会第二十一次会议决议公告 本次监事会无反对或弃权票。 本次监事会议案全部获得通过。 并根据相关规定对《公司章程》及附件《股东会议事规则》《董事会议事规则》 进行修订。 此议案尚需提交至公司2025年第三次临时股东会审议。 表决结果为：3 ...

证券代码：603233 证券简称：大参林 公告编号：2025-064 大参林医药集团股份有限公司 第四届董事会第二十八次会议决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗 漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 一、董事会会议召开情况 大参林医药集团股份有限公司（以下简称"公司"）第四届董事会第二十八 次会议通知于 2025 年 10 月 20 日发出，于 2025 年 10 月 29 日以通讯方式召开， 本次会议应到董事 8 人，实到董事 8 人。本次会议由董事长柯云峰先生召集并主 持，公司监事及部分高级管理人员列席了会议。本次会议的出席人数、召集、召 开及表决程序均符合《中华人民共和国公司法》（以下简称"《公司法》"）等法律 法规、行政部门规章、规范性文件和《大参林医药集团股份有限公司章程》（以 下简称"《公司章程》"）的规定，会议决议合法有效。 二、董事会会议审议情况 1、审议通过《关于公司 2025 年第三季度报告的议案》 根据《公司法》《证券法》《上海证券交易所股票上市规则》等法律法规及《公 司章程》等规章制度，按照中国证券监督管 ...

大参林医药集团股份有限公司 2025 年第三季度报告 证券代码：603233 证券简称：大参林 大参林医药集团股份有限公司 2025 年第三季度报告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗 漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真实、准确、完整，不存 在虚假记载、误导性陈述或重大遗漏，并承担个别和连带的法律责任。 公司负责人、主管会计工作负责人及会计机构负责人（会计主管人员）保证季度报告中财务信息 的真实、准确、完整。 第三季度财务报表是否经审计 □是 √否 一、主要财务数据 （一） 主要会计数据和财务指标 单位：元 币种：人民币 | | | 本报告期比 | | 年初至报告期 | | --- | --- | --- | --- | --- | | 项目 | 本报告期 | 上年同期增 | 年初至报告期末 | 末比上年同期 | | | | 减变动幅度 | | 增减变动幅度 | | | | (%) | | (%) | | 营业收入 | 6,545,672,910.36 | 2.51 | ...

证券代码：603233 证券简称：大参林 公告编号：2025-072 大参林医药集团股份有限公司 2025年半年度权益分派实施公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗 漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 每股分配比例 A 股每股现金红利0.34元 相关日期 | 股份类别 | 股权登记日 | 最后交易日 | 除权（息）日 | 现金红利发放日 | | --- | --- | --- | --- | --- | | Ａ股 | 2025/11/5 | － | 2025/11/6 | 2025/11/6 | 差异化分红送转： 是 （1）差异化分红方案 公司分别于 2024 年 3 月 15 日、2024 年 4 月 1 日召开第四届董事会第十三次会议、 2024 年第二次临时股东大会，审议通过了《关于以集中竞价交易方式回购公司股份方案 的议案》，同意公司以集中竞价交易方式回购公司股份，回购的股份全部用于后续实施股 权激励。回购资金总额不低于 1 亿元，不超过 2 亿元，资金来源为公司自有资金。回购期 限自公司 2024 年第二次临时股东大会审议 ...

Core Insights - In 2025, Dazhenglin Pharmaceutical Group achieved a revenue of 13.52 billion yuan, a year-on-year increase of 1.3%, and a net profit of 798 million yuan, up 21.4%, showcasing strong profitability amidst a declining retail pharmacy market [1] Group 1: National Expansion and Scale Effect - As of June 30, 2025, Dazhenglin had a total of 16,833 stores across 21 provinces, with 10,370 direct-operated and 6,463 franchised stores [2] - The company adopted a "self-built + acquisition + direct franchise" strategy, achieving breakthroughs in both existing market penetration and new market coverage [2] - In the East China market, Dazhenglin opened 134 new stores, reaching a total of 943 stores, and improved store efficiency by 18% in large stores and 12% in community stores [2] Group 2: Integration of Pet Economy and Retail Pharmacy - Dazhenglin entered the pet economy market, covering over 3,000 stores nationwide, contributing 12% to revenue [3] - The company established a consumption ecosystem through "drug retail + light medical services + ecological products," achieving a 68% repurchase rate in trial stores [3] - Dazhenglin launched its own pet food brand "CanPet" and set up a 406 million yuan pet industry fund to invest in pet healthcare and smart hardware [3] Group 3: Digitalization and Professional Services - The company implemented over ten digital projects, achieving a 93.54% online-to-offline service coverage and a 2.1 percentage point increase in online business gross margin [4] - Dazhenglin has a team of over 20,000 pharmacy professionals and provides medication therapy management services, serving over 3 million patients [4] - The AI system "AI Xiaosan" improved consultation efficiency, completing 4.7 million professional consultations in the first half of the year [4] Group 4: Social Responsibility and Business Success - In the first half of 2025, Dazhenglin distributed dividends and repurchased shares totaling 3.834 billion yuan, exceeding the total funds raised since its listing [5] - The company implemented recycling initiatives, saving over 21.57 million cardboard boxes, and reduced energy consumption by over 40% [5] - Dazhenglin's social initiatives provided health checks and medication safety education to over 1 million people [5] Group 5: Future Outlook - Dazhenglin aims to expand its market share through an integrated business model and a nationwide logistics network, with plans to invest 1 billion yuan in pet business over the next three years [6][7] - The company plans to establish 5,000 pet-friendly stores by 2028 and explore a "pet insurance + health management" payment model [7] - Dazhenglin is transitioning from regional leader to a global health service leader, driven by innovation and responsibility [7]

Group 1 - The core point of the announcement is that the controlling shareholder, Mr. Ke Jinlong, has released a portion of his pledged shares, specifically 31,680,000 shares, which represents 15.31% of his total holdings and 2.78% of the company's total share capital [1][1][1] Group 2 - The specific details of the share release include the number of shares released and the percentage of total holdings affected [1][1] - The announcement confirms that the release of the pledge has been completed and the registration procedures have been finalized [1]

Core Insights - The best-performing fund managed by Fang Min in Q3 2025 is the Fortune China Securities 500 Index Enhanced (LOF) Y, with a quarterly net value increase of 22.92% [1][2]. Fund Performance Summary - The Fortune China Securities 500 Index Enhanced (LOF) Y fund has a scale of 4.6 billion yuan and an annualized return of 9.22%, with a Q3 increase of 22.75% [2]. - The fund manager, Fang Min, has achieved a cumulative return of 150.55% during his tenure managing the Fortune China Securities 500 Index Enhanced (LOF) A fund, with an average annualized return of 8.75% [2]. - Fang Min has made 252 adjustments to the heavy positions in his managed funds, with a success rate of 62.3% [2]. Heavy Position Adjustment Cases - Notable successful stock adjustments include: - Qibin Group: Purchased in Q4 2019, sold in Q4 2021, with an estimated return of 249.25% and a company performance growth of 214.96% [3][5]. - China Shenhua: Purchased in Q3 2021, sold in Q3 2024, with an estimated return of 87.59% and a company performance growth of 17.15% [5]. - Conversely, some stocks resulted in losses: - Robot: Purchased in Q2 2015, sold in Q4 2018, with an estimated return of -59.85% despite a company performance growth of 83.62% [4][5]. Additional Fund Information - The Fortune China Securities 500 Index Enhanced (LOF) C fund has a scale of 849 million yuan and a Q3 increase of 22.68% [2]. - The Fortune China Securities 1000 Index Enhanced (LOF) C fund has a scale of 392 million yuan and a Q3 increase of 20.69% [2].

Group 1 - The core announcement is about the release of part of the pledged shares by the controlling shareholder, Mr. Ke Jinlong, who has released 31,680,000 shares [1][3] - The released shares represent 15.31% of Mr. Ke Jinlong's total holdings and 2.78% of the company's total share capital [3] - The announcement confirms that the company’s board of directors guarantees the truthfulness, accuracy, and completeness of the content [1] Group 2 - The announcement was made on October 28, 2025, following the completion of the pledge release registration procedures [3] - The document includes a reminder that all data in the tables may have rounding differences [1]

Core Points - Dacilin announced on October 27 that it received a notification from its controlling shareholder, Mr. Ke Jinlong, regarding the release of a portion of his pledged shares, totaling 31,680,000 shares [1] Summary by Category Company Actions - Dacilin has completed the registration procedures for the release of the pledged shares [1] Shareholder Information - Mr. Ke Jinlong, a controlling shareholder, is the individual who notified the company about the release of the pledged shares [1]

证券代码：603233 证券简称：大参林 公告编号：2025-063 大参林医药集团股份有限公司 关于控股股东部分股份解除质押的公告 一、本次股份解除质押的具体情况 | | | | | | | | | 已质押股份情况 | 未质押股份情 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | | | | | | 占其所 | 占公 | | | 况 | 未质 | | | 持股数量 | 持股 | 本次质押前 | 本次质押后 | 持股份 | 司总 | 已质押 | 已质押 | 未质押 | 押股 | | 股东名称 | （股） | 比例 | 累计质押数 | 累计质押数 | 比例 | 股本 | 股份中 | 股份中 | 股份中 | 份中 | | | | (%) | 量（股） | 量（股） | | 比例 | 限售股 | | 限售股 | | | | | | | | （%） | （%） | 份数量 | 冻结股 | 份数量 | 冻结 | | | | | | | | | | 份数量 | | 股份 | | | | | | | | | （股） | | ...